In particular, the overactivity of exportin 1 (XPO1/CRM1) in various cancers, such as ovarian carcinoma, glioma, and pancreatic cancer, highlights the need to target both NPC function and nuclear export processes in therapeutic strategies. The gene discussed is XPO1; the disease is glioma.